ABBV vs CLDX
ABBV: Global biopharmaceutical company with leadership positions in immunology, neuroscience, oncology, and aesthetics targeting complex diseases. CLDX: A clinical-stage biopharmaceutical company developing mast cell-targeted monoclonal and bispecific antibodies for chronic urticaria, inflammatory skin diseases, and systemic inflammatory conditions.
Side-by-side fundamentals
| Metric | ABBV | CLDX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $253.30 | $34.77 | |
| Market cap as of 2026-07-23 | $452.5B | $2.7B | |
| P/E as of 2026-07-23 | 124.48 | n/a | |
| PEG as of 2026-07-23 | 5.72 | -0.14 | CLDX lower |
| Net margin as of 2026-07-23 | +5.8% | -25011.8% | ABBV higher |
| Gross margin as of 2026-07-23 | +72.0% | +17.6% | ABBV higher |
| Operating margin as of 2026-07-23 | +24.4% | -27187.6% | ABBV higher |
| ROE as of 2026-07-23 | +95.6% | -50.7% | ABBV higher |
| ROA as of 2026-07-23 | +2.7% | -46.6% | ABBV higher |
| Debt / equity as of 2026-07-23 | 49.22 | 0.00 | CLDX lower |
| Revenue growth (YoY) as of 2026-07-23 | +9.5% | -88.5% | ABBV higher |
| Revenue CAGR (3y) SEC XBRL | +1.8% | -13.1% | ABBV higher |
| Dividend yield as of 2026-07-23 | +2.7% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-23 | 0.27 | 0.82 | |
| 1-year return as of 2026-07-22 close | +35.4% | +55.5% | CLDX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.